Shanathan Sritharan

Shanathan Sritharan

Auto-generated profile, based on publicly available information

Shanathan Sritharan

Hunter New England Local Health District, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Hypertension
Verified
Journal Article
Closed access
PDF file
LBLloyd E. Butel-Simoes
Lloyd E. Butel-Simoes
THTatt Jhong Haw
Tatt Jhong Haw
TWTrent Williams
Trent Williams
SSShanathan Sritharan
Shanathan Sritharan
PGPayal Gadre
Payal Gadre
Aaron SverdlovAaron Sverdlov
Aaron Sverdlov
Cardiovascular disease and cancer are 2 of the leading causes of death worldwide. Although improvements in outcomes have been noted for both disease entities, the success of cancer therapies has come at the cost of at times very impactful adverse events such as cardiovascular events. Hypertension has been noted as both, a side effect as well as a risk factor for the cardiotoxicity of cancer therapies. Some of these dynamics are in keeping with the role of hypertension as a cardiovascular risk factor not only for heart failure, but also for the development of coronary and cerebrovascular disease, and kidney disease and its association with a higher morbidity and mortality overall. Other aspects such as the molecular mechanisms underlying the amplification of acute and long-term cardiotoxicity risk of anthracyclines and increase in blood pressure with various cancer therapeutics remain to be elucidated. In this review, we cover the latest clinical data regarding the risk of hypertension across a spectrum of novel anticancer therapies as well as the underlying known or postulated pathophysiological mechanisms. Furthermore, we review the acute and long-term implications for the amplification of the development of cardiotoxicity with drugs not commonly associated with hypertension such as anthracyclines. An outline of management strategies, including pharmacological and lifestyle interventions as well as models of care aimed to facilitate early detection and more timely management of hypertension in patients with cancer and survivors concludes this review, which overall aims to improve both cardiovascular and cancer-specific outcomes.

18 October 2024 in JACC: Advances
Verified
Journal Article
Open access
SSShanathan Sritharan
Shanathan Sritharan
BWBradley Wilsmore
Bradley Wilsmore
JWJohn Wiggers
John Wiggers
LBLloyd Butel-Simoes
Lloyd Butel-Simoes
KFKristy Fakes
Kristy Fakes
TWTrent Williams
Trent Williams
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality and residing in a rural and remote region is associated with an increased risk. The impact of rurality on CVD outcomes needs to be fully elucidated. The purpose of this study was to assess the difference in mortality, readmission within 30 days, total readmissions, survival, and total emergency department (ED) presentations following an index CVD admission among patients from rural or remote areas as compared to metropolitan areas. This retrospective observational study included all index hospitalizations with heart failure (HF), atrial fibrillation (AF), or acute coronary syndrome (ACS) within the Hunter New England region of Australia, between January 1, 2008, and December 31, 2021. There were 27,995 ACS admissions, 15,586 HF admissions, and 16,935 AF admissions. Patients from a rural or remote area presenting with CVD presentations had increased 30-day readmission (OR: 1.19; P < 0.001), an increased number of readmissions (incident rate ratio: 1.19; P < 0.001), and more ED presentations (incident rate ratio: 1.39; P < 0.001) as compared to patients from metropolitan areas. This was consistent across patients presenting with ACS, HF, and AF. There was no difference in mortality (HR: 1.01; P = 0.515). However, in the ACS subgroup, there was increased mortality in the rural and remote population (HR: 1.05; P = 0.015). This study highlights the increased incidence of ED presentations and hospital readmissions, for those living in rural Australia, illustrating the disparity in health care provided, and the ongoing need for interventions that address poorer access to specialized health care in the early discharge phase of hospitalization.

8 January 2025 in Internal Medicine Journal
Verified
Journal Article
Closed access
SSShanathan Sritharan
Shanathan Sritharan
KMKindelan Murray
Kindelan Murray
DLDominic Lam
Dominic Lam
DWDaniel Wittaker
Daniel Wittaker
ASAaron Sverdlov
Aaron Sverdlov
NCNicholas Collins
Nicholas Collins

1 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MFMatthew French
Matthew French
GMGeorgia Meagher
Georgia Meagher
CCChristopher Ray Chen
Christopher Ray Chen
FDFiona Dee
Fiona Dee
LSLindsay Savage
Lindsay Savage
ABAndrew Boyle
Andrew Boyle
Background: Rural and remote patients presenting with acute coronary syndrome (ACS) experience delays in diagnosis and reperfusion, contributing to higher mortality than those presenting to tertiary centres. Evidence supporting system-triggered diagnostic interventions across the full spectrum of ACS remains limited. Methods: In a multicentre, cluster-randomized controlled trial, 29 rural emergency departments in New South Wales, Australia, were assigned to either a system-triggered diagnostic telemedical support from a tertiary centre (MORACS intervention) or usual care. Adult patients presenting with symptoms consistent with ACS were included in the study. The primary outcome was all-cause death. Secondary outcomes included 30-day and 1-year death, length of hospital stay and 30-day readmission rate. Results: Between December 2018 and April 2020, ACS was confirmed in 587 of 7474 emergency department presentations consistent with possible ACS. Of these, 274 (47%) presented to MORACS intervention hospitals and 313 (53%) presented to control hospitals. Over a median follow-up of 62 months, all-cause death occurred in 54 patients (20%) in the intervention group and 85 patients (27%) in the control group, representing a 30% lower risk of death with the MORACS intervention (HR 0.70; 95% CI, 0.49–0.98; P = 0.036). The mortality benefit was consistent across both the ST-elevation ACS (STEACS) and non-ST elevation ACS (NSTEACS) subgroups. No significant differences were observed in length of stay or 30-day readmissions. Conclusions: The MORACS intervention significantly reduced all-cause mortality among rural patients with ACS. These findings support the integration of system-triggered diagnostic telehealth support into rural emergency department settings to improve outcomes in ACS management. Registration: ACTRN12619000533190 (anzctr.org.au) Clinical Perspective: What is New?: In this multicentre cluster-randomized controlled trial, system-triggered diagnostic telemedical support in rural emergency departments significantly reduced all-cause mortality in patients presenting with ACS. This larger cohort extends the findings of the initial MORACs study, demonstrating a mortality benefit of diagnostic telemedical support across the full spectrum of ACS presentations, including both STEACS and NSTEACS. What Are the Clinical Implications?: Implementing system-triggered diagnostic telemedical support can help overcome barriers to timely diagnosis and reperfusion in geographically isolated hospitals. Broader implementation of such interventions may enhance equity in cardiac care delivery and reduce rural-urban disparities in ACS outcomes.